About Regeneron
regeneron.com- Founded 1988
- Ticker REGN
REGN 609.94 USD -0.25%
- Revenue (FY2025) $14.34B
- Net income $4.50B
Investor research: Yahoo Finance · SEC filings
Source: Wikipedia
Regeneron
To apply for this job please visit regeneron.wd1.myworkdayjobs.com.
Working in RENSSELAER
What people say about Regeneron
- An effective eye drug is $50, but many doctors choose a $2,000 alternative
- Hospitals and universities repurposing drugs at lower cost
- FDA approves first gene therapy for treatment of genetic hearing loss
- FDA approves first gene therapy for treatment of genetic hearing loss
Recent news
- Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact - Fierce Biotech
- A man for all markets returns to the Regeneron Science Talent Search - Society for Science
- How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story - Trefis
- Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now? - Yahoo Finance
- Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Aggregated from public discussions and news; opinions are the authors’ own.
More jobs at Regeneron
- Senior Director, Patient Advocacy
- Sales Specialist Immunology (f/m/d) – Heidelberg – Mainz – Trier – Saarbrücken
- Associate Director, Global Patient Advocacy
- Sales Specialist Immunology (f/m/d) – Trier – Saarbrücken – Kaiserslautern – Ludwigshafen
- Associate Director, CMC Regulatory Affairs (Hematology/Oncology)
Keep exploring on Get A Job.ai
Not quite the right fit? Your next opportunity is a click away.
- Browse all jobs
- More jobs by category
- Remote jobs you can do from anywhere
- Research typical pay for this role
- Set a job alert so new matches reach you first
- Upload your resume to apply faster
Hiring instead? Post a job and reach candidates searching right now.